Alzamend Neuro Approves Reverse Stock Split to Maintain Nasdaq Listing – Shares Decline
Alzamend Neuro, a clinical-stage biopharmaceutical company dedicated to advancing innovative treatments for Alzheimer’s disease, bipolar disorder, major depressive disorder, and PTSD, announced today that its
